Immune escape of tumors: Apoptosis resistance and tumor counterattack

Journal of Leukocyte Biology

Volumn 71, Issue 6, 2002, Pages 907-920

  Igney, Frederik H ^a   Krammer, Peter H ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

CD95; CD95L; Cytotoxic T cells; Death receptor; Immunosuppression

Indexed keywords

CASPASE 8; FAS ANTIGEN; FAS LIGAND;

ANTIGEN PRESENTATION; APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CYTOTOXIC T LYMPHOCYTE; EXOCYTOSIS; IMMUNE DEFICIENCY; IMMUNE MEDIATED INJURY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW;

ANIMALS; APOPTOSIS; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 0036623140     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (260)

1. Smyth, M. J., Godfrey, D. I., Trapani, J. A. (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2, 293-299.
2. Sogn, J. A. (1998) Tumor immunology: the glass is half full. Immunity 9, 757-763.
3. Rosenberg, S. A. (2001) Progress in human tumour immunology and immunotherapy. Nature 411, 380-384.
4. Houghton, A. N., Gold, J. S., Blachere, N. E. (2001) Immunity against cancer: lessons learned from melanoma. Curr. Opin. Immunol. 13, 134-140.
5. Boon, T., van der Bruggen, P. (1996) Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725-729.
6. Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., Roederer, M., Davis, M. M. (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5, 677-685.
7. Wortzel, R. D., Philipps, C., Schreiber, H. (1983) Multiple tumour-specific antigens expressed on a single tumour cell. Nature 304, 165-167.
8. Burnet, F. M. (1970) The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1-27.
9. Fuchs, E. J., Matzinger, P. (1996) Is cancer dangerous to the immune system? Semin. Immunol. 8, 271-280.
10. Watzl, C., Long, E. O. (2000) Exposing tumor cells to killer cell attack. Nat. Med. 6, 867-868.
11. Pardoll, D. M. (2001) Immunology, Stress, NK receptors, and immune surveillance. Science 294, 534-536.
12. Moretta, A., Biassoni, R., Bottino, C., Mingari, M. C., Moretta, L. (2000) Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol. Today 21, 228-234.
13. Cerwenka, A., Bakker, A. B., McClanahan, T., Wagner, J., Wu, J., Phillips, J. H., Lanier, L. L. (2000) Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12, 721-727.
14. Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., Spies, T. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727-729.
15. Wu, J., Song, Y., Bakker, A. B., Bauer, S., Spies, T., Lanier, L. L., Phillips, J. H. (1999) An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285, 730-732.
16. Lollini, P. L., Forni, G. (1999) Specific and nonspecific immunity in the prevention of spontaneous tumours. Immunol Today 20, 347-350.
17. Di Carlo, E., Forni, G., Lollini, P., Colombo, M. P., Modesti, A., Musiani, P. (2001) The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97, 339-345.
18. Elgert, K. D., Alleva, D. G., Mullins, D. W. (1998) Tumor-induced immune dysfunction: the macrophage connection. J. Leukoc. Biol. 64, 275-290.
19. Bonnotte, B., Larmonier, N., Favre, N., Fromentin, A., Moutet, M., Martin, M., Gurbuxani, S., Solary, E., Chauffert, B., Martin, F. (2001) Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J. Immunol. 167, 5077-5083.
20. Lin, E. Y., Nguyen, A. V., Russell, R. G., Pollard, J. W. (2001.) Colonystimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193, 727-740.
21. Chen, L. (1998) Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol. Today 19, 27-30.
22. Ochsenbein, A. F., Klenerman, P., Karrer, U., Ludewig, B., Pericin, M., Hengartner, H., Zinkernagel, R. M. (1999) Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA 96, 2233-2238.
23. Ochsenbein, A. F., Sierro, S., Odermatt, B., Pericin, M., Karrer, U., Hermans, J., Hemmi, S., Hengartner, H., Zinkernagel, R. M. (2001) Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058-1064.
24. Rocha, G., Deschenes, J., Rowsey, J. J. (1998) The immunology of corneal graft rejection. Crit. Rev. Immunol. 18, 305-325.
25. Onrust, S. V., Hartl, P. M., Rosen, S. D., Hanahan, D. (1996) Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. J. Clin. Investig. 97, 54-64.
26. Piali, L., Fichtel, A., Terpe, H. J., Imhof, B. A., Gisler, R. H. (1995) Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J. Exp. Med. 181, 811-816.
27. Ishido, S., Choi, J. K., Lee, B. S., Wang, C., DeMaria, M., Johnson, R. P., Cohen, G. B., Jung, J. U. (2000) Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity 13, 365-374.
28. Singh, S., Ross, S. R., Acena, M., Rowley, D. A., Schreiber, H. (1992) Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175, 139-146.
29. Wick, M., Dubey, P., Koeppen, H., Siegel, C. T., Fields, P. E., Chen, L., Bluestone, J. A., Schreiber, H. (1997) Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186, 229-238.
30. Antonia, S. J., Extermann, M., Flavell, R. A. (1998) Immunologic non-responsiveness to tumors. Crit. Rev. Oncog. 9, 35-41.
31. Villunger, A., Strasser, A. (1999) The great escape: is immune evasion required for tumor progression? Nat. Med. 5, 874-875.
32. Gilboa, E. (1999) How tumors escape immune destruction and what we can do about it. Cancer Immunol. Immunother. 48, 382-385.
33. Maeurer, M. J., Gollin, S. M., Martin, D., Swaney, W., Bryant, J., Castelli, C., Robbins, P., Parmiani, G., Storkus, W. J., Lotze, M. T. (1996) Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Investig. 98, 1633-1641.
34. Kim, U., Baumler, A., Carruthers, C., Bielat, K. (1975) Immunological escape mechanism in spontaneously metastasizing mammary tumors. Proc. Natl. Acad. Sci. USA 72, 1012-1016.
35. Vasmel, W. L., Sijts, E. J., Leupers, C. J., Matthews, E. A., Melief, C. J. (1989) Primary virus-induced lymphomas evade T cell immunity by failure to express viral antigens. J. Exp. Med. 169, 1233-1254.
36. Stackpole, C. W., Cremona, P., Leonard, C., Stremmel, P. (1980) Antigenic modulation as a mechanism for tumor escape from immune destruction: identification of modulation-positive and modulation-negative mouse lymphomas with xenoantisera to murine leukemia virus gp70. J. Immunol. 125, 1715-1723.
37. Hicklin, D. J., Marincola, F. M., Ferrone, S. (1999) HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol. Med. Today 5, 178-186.
38. Garrido, F., Ruiz-Cabello, F., Cabrera, T., Perez-Villar, J. J., Lopez-Botet, M., Duggan-Keen, M., Stern, P. L. (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18, 89-95.
39. Bicknell, D. C., Rowan, A., Bodmer, W. F. (1994) Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc. Natl. Acad. Sci. USA 91, 4751-4756.
40. Seung, S., Urban, J. L., Schreiber, H. (1993) A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. J. Exp. Med. 178, 933-940.
41. Natali, P. G., Nicotra, M. R., Bigotti, A., Venture, I., Marcenaro, L., Giacomini, P., Russo, C. (1989) Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc. Natl. Acad. Sci. USA 86, 6719-6723.
42. Blanchet, O., Bourge, J. F., Zinszner, H., Israel, A., Kourilsky, P., Dausset, J., Degos, L., Paul, P. (1992) Altered binding of regulatory factors to HLA class I enhancer sequence in human tumor cell lines lacking class I antigen expression. Proc. Natl. Acad. Sci. USA 89, 3488-3492.
43. Bosshart, H., Jarrett, R. F. (1998) Deficient major histocompatibility complex class II antigen presentation in a subset of Hodgkin's disease tumor cells. Blood 92, 2252-2259.
44. Farrell, H. E., Vally, H., Lynch, D. M., Fleming, P., Shellam, G. R., Scalzo, A. A., Davis-Poynter, N. J. (1997) Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature 386, 510-514.
45. Cretney, E., Degli-Esposti, M. A., Densley, E. H., Farrell, H. E., Davis-Poynter, N. J., Smyth, M. J. (1999) m144, a murine cytomegalovirus (MCMV)-encoded major histocompatibility complex class I homologue, confers tumor resistance to natural killer cell-mediated rejection. J. Exp. Med. 190, 435-444.
46. Seliger, B., Maeurer, M. J., Ferrone, S. (1997) TAP off - tumors on. Immunol. Today 18, 292-299.
47. Restifo, N. P., Esquivel, F., Kawakami, Y., Yewdell, J. W., Mule, J. J., Rosenberg, S. A., Bennink, J. R. (1993) Identification of human cancers deficient in antigen processing. J. Exp. Med. 177, 265-272.
48. Rotem-Yehudar, R., Groettrup, M., Soza, A., Kloetzel, P. M., Ehrlich, R. (1996) LMP-associated proteolytic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. J. Exp. Med. 183, 499-514.
49. Cromme, F. V., Airey, J., Heemels, M. T., Ploegh, H. L., Keating, P. J., Stern, P. L., Meijer, C. J., Walboomers, J. M. (1994) Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 179, 335-340.
50. Johnsen, A. K., Templeton, D. J., Sy, M., Harding, C. V. (1999) Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J. Immunol. 163, 4224-4231.
51. Ossendorp, F., Eggers, M., Neisig, A., Ruppert, T., Groettrup, M., Sijts, A., Mengede, E., Kloetzel, P. M., Neefjes, J., Koszinowski, U., Melief, C. (1996) A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity 5, 115-124.
52. Chouaib, S., Asselin-Paturel, C., Mami-Chouaib, F., Caignard, A., Blay, J. Y. (1997) The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today 18, 493-497.
53. Loeffler, C. M., Smyth, M. J., Longo, D. L., Kopp, W. C., Harvey, L. K., Tribble, H. R., Tase, J. E., Urba, W. J., Leonard, A. S., Young, H. A., et. al. (1992) Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells. J. Immunol. 149, 949-956.
54. Pasche, B. (2001) Role of transforming growth factor beta in cancer. J. Cell. Physiol. 186, 153-168.
55. Gorelik, L., Flavell, R. A. (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 7, 1118-1122.
56. Tada, T., Ohzeki, S., Utsumi, K., Takiuchi, H., Muramatsu, M., Li, X. F., Shimizu, J., Fujiwara, H., Hamaoka, T. (1991) Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J. Immunol. 146, 1077-1082.
57. Ranges, G. E., Figari, I. S., Espevik, T., Palladino Jr., M. A. (1987) Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J. Exp. Med. 166, 991-998.
58. Torre-Amione, G., Beauchamp, R. D., Koeppen, H., Park, B. H., Schreiber, H., Moses, H. L., Rowley, D. A. (1990) A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA 87, 1486-1490.
59. Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., Carbone, D. P. (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2, 1096-1103.
60. Plescia, O. J., Smith, A. H., Grinwich, K. (1975) Subversion of immune system by tumor cells and role of prostaglandins. Proc. Natl. Acad. Sci. USA 72, 1848-1851.
61. Young, M. R., Knies, S. (1984) Prostaglandin E production by Lewis lung carcinoma: mechanism for tumor establishment in vivo. J. Natl. Cancer Inst. 72, 919-922.
62. McLemore, T. L., Hubbard, W. C., Litterst, C. L., Liu, M. C., Miller, S., McMahon, N. A., Eggleston, J. C.,Boyd, M. R. (1988) Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res. 48, 3140-3147.
63. Matsuda, M., Salazar, F., Petersson, M., Masucci, G., Hansson, J., Pisa, P., Zhang, Q. J., Masucci, M. G., Kiessling, R. (1994) Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J. Exp. Med. 180, 2371-2376.
64. Oghiso, Y., Yamada, Y., Ando, K., Ishihara, H., Shibata, Y. (1993) Differential induction of prostaglandin E2-dependent and -independent immune suppressor cells by tumor-derived GM-CSF and M-CSF. J. Leukoc. Biol. 53, 86-92.
65. Sotomayor, E. M., Fu, Y. X., Lopez-Cepero, M., Herbert, L., Jimenez, J. J., Albarracin, C., Lopez, D. M. (1991) Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor. J. Immunol. 147, 2816-2823.
66. McKallip, R., Li, R., Ladisch, S. (1999) Tumor gangliosides inhibit the tumor-specific immune response. J. Immunol. 163, 3718-3726.
67. Nakashima, M., Sonoda, K., Watanabe, T. (1999) Inhibition of cell growth and induction of apoptotic cell death by the human tumorassociated antigen RCAS1. Nat. Med. 5, 938-942.
68. Kiessling, R., Wasserman, K., Horiguchi, S., Kono, K., Sjoberg, J., Pisa, P., Petersson, M. (1999) Tumor-induced immune dysfunction. Cancer Immunol. Immunother. 48, 353-362.
69. Arnold, B., Schonrich, G., Hammerling, G. J. (1993) Multiple levels of peripheral tolerance. Immunol. Today 14, 12-14.
70. Ganss, R., Limmer, A., Sacher, T., Arnold, B., Hammerling, G. J. (1999) Autoaggression and tumor rejection: it takes more than self-specific T-cell activation. Immunol. Rev. 169, 263-272.
71. Chen, L., Ashe, S., Brady, W. A., Hellstrom, I., Hellstrom, K. E., Ledbetter, J. A., McGowan, P., Linsley, P. S. (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-1102.
72. Guinan, E. C., Gribben, J. G., Boussiotis, V. A., Freeman, G. J., Nadler, L. M. (1994) Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84, 3261-3282.
73. Staveley-O'Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D., Levitsky, H. (1998) Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95, 1178-1183.
74. Becker, J. C., Brabletz, T., Czerny, C., Termeer, C., Brocker, E. B. (1993) Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma. Int. Immunol. 5, 1501-1508.
75. Shrikant, P., Khoruts, A., Mescher, M. F. (1999) CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 11, 483-493.
76. Maeda, H., Shiraishi, A. (1996) TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J. Immunol. 156, 73-78.
77. Qin, Z., Richter, G., Schuler, T., Ibe, S., Cao, X., Blankenstein, T. (1998) B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 4, 627-630.
78. Sakaguchi, S. (2000) Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101, 455-458.
79. Matsui, S., Ahlers, J. D., Vortmeyer, A. O., Terabe, M., Tsukui, T., Carbone, D. P., Liotta, L. A., Berzofsky, J. A. (1999) A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J. Immunol. 163, 184-193.
80. Takahashi, K., Ono, K., Hirabayashi, Y., Taniguchi, M. (1988) Escape mechanisms of melanoma from immune system by soluble melanoma antigen. J. Immunol. 140, 3244-3248.
81. Russell, J. H., White, C. L., Loh, D. Y., Meleedy-Rey, P. (1991) Receptor-stimulated death pathway is opened by antigen in mature T cells. Proc. Natl. Acad. Sci. USA 88, 2151-2155.
82. Radvanyi, L. G., Mills, G. B., Miller, R. G. (1993) Religation of the T cell receptor after primary activation of mature T cells inhibits proliferation and induces apoptotic cell death. J. Immunol. 150, 5704-5715.
83. Martin, D. R., Miller, R. G. (1989) In vivo administration of histoincompatible lymphocytes leads to rapid functional deletion of cytotoxic T lymphocyte precursors. J. Exp. Med. 170, 679-690.
84. Kirchhoff, S., Muller, W. W., Krueger, A., Schmitz, I., Krammer, P. H. (2000) TCR-mediated up-regulation of c-FLIPshort correlates with resistance toward CD95-mediated apoptosis by blocking death-inducing signaling complex activity. J. Immunol. 165, 6293-6300.
85. Singer, G. G., Abbas, A. K. (1994) The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1, 365-371.
86. Dhein, J., Walczak, H., Baumler, C., Debatin, K. M., Krammer, P. H. (1995) Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373, 438-441.
87. Brunner, T., Mogil, R. J., LaFace, D., Yoo, N. J., Mahboubi, A., Echeverri, F., Martin, S. J., Force, W. R., Lynch, D. H., Ware, C. F., et al. (1995) Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373, 441-444.
88. Li-Weber, M., Laur, O., Hekele, A., Coy, J., Walczak, H., Krammer, P. H. (1998) A regulatory element in the CD95 (APO-1/Fas) ligand promoter is essential for responsiveness to TCR-mediated activation. Eur. J. Immunol. 28, 2373-2383.
89. Kirchhoff, S., Muller, W. W., Li-Weber, M., Krammer, P. H. (2000) Up-regulation of c-FLIPshort and reduction of activation-induced cell death in CD28-costimulated human T cells. Eur. J. Immunol. 30, 2765-2774.
90. Bogen, B. (1996) Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur. J. Immunol. 26, 2671-2679.
91. Lauritzsen, G. F., Hofgaard, P. O., Schenck, K., Bogen, B. (1998) Clonal deletion of thymocytes as a tumor escape mechanism. Int. J. Cancer 78, 216-222.
92. Shresta, S., Pham, C. T., Thomas, D. A., Graubert, T. A., Ley, T. J. (1998) How do cytotoxic lymphocytes kill their targets? Curr. Opin. Immunol. 10, 581-587.
93. Rouvier, E., Luciani, M. F., Golstein, P. (1993) Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J. Exp. Med. 177, 195-200.
94. Walsh, C. M., Glass, A. A., Chiu, V., Clark, W. R. (1994) The role of the Fas lytic pathway in a perforin-less CTL hybridoma. J. Immunol. 153, 2506-2514.
95. Li, J. H., Rosen, D., Ronen, D., Behrens, C. K., Krammer, P. H., Clark, W. R., Berke, G. (1998) The regulation of CD95 ligand expression and function in CTL. J. Immunol. 161, 3943-3949.
96. Smyth, M. J., Cretney, E., Takeda, K., Wiltrout, R. H., Sedger, L. M., Kayagaki, N., Yagita, H., Okumura, K. (2001) Tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) contributes to interferon gammadependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193, 661-670.
97. Takeda, K., Hayakawa, Y., Smyth, M. J., Kayagaki, N., Yamaguchi, N., Kakuta, S., Iwakura, Y., Yagita, H., Okumura, K. (2001) Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med. 7, 94-100.
98. Takeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita, H., Okumura, K. (2002) Critical role for tumor necrosis factorrelated apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195, 161-169.
99. Krammer, P. H. (1999) CD95(APO-1/Fas)-mediated apoptosis: live and let die. Adv. Immunol. 71, 163-210.
100. Schmitz, I., Kirchhoff, S., Krammer, P. H. (2000) Regulation of death receptor-mediated apoptosis pathways. Int. J. Biochem. Cell Biol. 32, 1123-1136.
101. Pitti, R. M., Marsters, S. A., Lawrence, D. A., Roy, M., Kischkel, F. C., Dowd, P., Huang, A., Donahue, C. J., Sherwood, S. W., Baldwin, D. T., Godowski, P. J., Wood, W. I., Gurney, A. L., Hillan, K. J., Cohen, R. L., Goddard, A. D., Botstein, D., Ashkenazi, A. (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396, 699-703.
102. Yu, K. Y., Kwon, B., Ni, J., Zhai, Y., Ebner, R., Kwon, B. S. (1999) A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J. Biol. Chem. 274, 13733-13736.
103. Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H., Peter, M. E. (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14, 5579-5588.
104. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., Dixit, V. M. (1996) FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85, 817-827.
105. Sprick, M. R., Weigand, M. A., Rieser, E., Rauch, C. T., Juo, P., Blenis, J., Krammer, P. H., Walczak, H. (2000) FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12, 599-609.
106. Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., Ashkenazi, A. (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12, 611-620.
107. Kischkel, F. C., Lawrence, D. A., Tinel, A., LeBlanc, H., Virmani, A., Schow, P., Gazdar, A., Blenis, J., Arnott, D., Ashkenazi, A. (2001) Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J. Biol. Chem. 276, 46639-46646.
108. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K. M., Krammer, P. H., Peter, M. E. (1998) Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17, 1675-1687.
109. Zamzami, N., Kroemer, G. (2001) The mitochondrion in apoptosis: how Pandora's box opens. Nat. Rev. Mol. Cell. Biol. 2, 67-71.
110. Martinou, J. C., Green, D. R. (2001) Breaking the mitochondrial barrier. Nat. Rev. Mol. Cell. Biol. 2, 63-67.
111. Rathmell, J. C., Thompson, C. B. (1999) The central effectors of cell death in the immune system. Annu. Rev. Immunol. 17, 781-828.
112. Krueger, A., Baumann, S., Krammer, P. H., Kirchhoff, S. (2001.) FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol. Cell. Biol. 21, 8247-8254.
113. Deveraux, Q. L., Reed, J. C. (1999) IAP family proteins - suppressors of apoptosis. Genes Dev. 13, 239-252.
114. Verhagen, A. M., Ekert, P. G., Pakusch, M., Silke, J., Connolly, L. M., Reid, G. E., Moritz, R. L., Simpson, R. J., Vaux, D. L. (2000) Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102, 43-53.
115. Du, C., Fang, M., Li, Y., Li, L., Wang, X. (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33-42.
116. van den Broek, M. E., Kagi, D., Ossendorp, F., Toes, R., Vamvakas, S., Lutz, W. K., Melief, C. J., Zinkernagel, R. M., Hengartner, H. (1996) Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184, 1781-1790.
117. Kagi, D., Ledermann, B., Burki, K., Seiler, P., Odermatt, B., Olsen, K. J., Podack, E. R., Zinkernagel, R. M., Hengartner, H. (1994) Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369, 31-37.
118. Lowin, B., Beermann, F., Schmidt, A., Tschopp, J. (1994) A null mutation in the perforin gene impairs cytolytic T lymphocyte- and natural killer cell-mediated cytotoxicity. Proc. Natl. Acad. Sci. USA 91, 11571-11575.
119. Heusel, J. W., Wesselschmidt, R. L., Shresta, S., Russell, J. H., Ley, T. J. (1994) Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 76, 977-987.
120. Sarin, A., Williams, M. S., Alexander-Miller, M. A., Berzofsky, J. A., Zacharchuk, C. M., Henkart, P. A. (1997) Target cell lysis by CTL granule exocytosis is independent of ICE/Ced-3 family proteases. Immunity 6, 209-215.
121. Medema, J. P., Toes, R. E., Scaffidi, C., Zheng, T. S., Flavell, R. A., Melief, C. J., Peter, M. E., Offringa, R., Krammer, P. H. (1997) Cleavage of FLICE (caspase-8) by granzyme B during cytotoxic T lymphocyte-induced apoptosis. Eur. J. Immunol. 27, 3492-3498.
122. Heibein, J. A., Coping, I. S., Barry, M., Pinkoski, M. J., Shore, G. C., Green, D. R., Bleackley, R. C. (2000) Cranzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members Bid and Bax. J. Exp. Med. 192, 1391-1402.
123. van den Broek, M. E., Kagi, D., Ossendorp, F., Toes, R., Vamvakas, S., Lutz, W. K., Melief, C. J., Zinkernagel, R. M., Hengartner, H. (1996) Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184, 1781-1790.
124. Smyth, M. J., Thia, K. Y., Street, S. E., MacGregor, D., Godfrey, D. I., Trapani, J. A. (2000) Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192, 755-760.
125. Mullbacher, A., Waring, P., Tha Hla, R., Tran, T., Chin, S., Stehle, T., Museteanu, C., Simon, M. M. (1999) Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes. Proc. Natl. Acad. Sci. USA 96, 13950-13955.
126. Davis, J. E., Smyth, M. J., Trapani, J. A. (2001) Granzyme A- and B-deficient killer lymphocytes are defective in eliciting DNA fragmentation but retain potent in vivo anti-tumor capacity. Eur. J. Immunol. 31, 39-47.
127. Witko-Sarsat, V., Rieu, P., Descamps-Latscha, B., Lesavre, P., Halbwachs-Mecarelli, L. (2000) Neutrophils: molecules, functions and pathophysiological aspects. Lab. Investig. 80, 617-653.
128. Babior, B. M. (1999) NADPH oxidase: an update. Blood 93, 1464-1476.
129. Bastian, N. R., Hibbs Jr., J. B. (1994) Assembly and regulation of NADPH oxidase and nitric oxide synthase. Curr. Opin. Immunol. 6, 131-139.
130. Hampton, M. B., Kettle, A. J., Winterbourn, C. C. (1998) Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 92, 3007-3017.
131. Bogdan, C., Rollinghoff, M., Diefenbach, A. (2000) The role of nitric oxide in innate immunity. Immunol. Rev. 173, 17-26.
132. Gudmundsson, G. H., Agerberth, B. (1999) Neutrophil antibacterial peptides, multifunctional effector molecules in the mammalian immune system. J. Immunol. Methods 232, 45-54.
133. Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., Schreiber, R. D. (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111.
134. Davidson, W. F., Giese, T., Fredrickson, T. N. (1998) Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J. Exp. Med. 187, 1825-1838.
135. Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J. L., Schroter, M., Burns, K., Mattmann, C., Rimoldi, D., French, L. E., Tschopp, J. (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388, 190-195.
136. Kataoka, T., Schroter, M., Hahne, M., Schneider, P., Irmler, M., Thome, M., Froelich, C. J., Tschopp, J. (1998) FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J. Immunol. 161, 3936-3942.
137. Medema, J. P., de Jong, J., van Hall, T., Melief, C. J., Offringa, R. (1999) Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 190, 1033-1038.
138. Taylor, M. A., Chaudhary, P. M., Klem, J., Kumar, V., Schatzle, J. D., Bennett, M. (2001) Inhibition of the death receptor pathway by cFLIP confers partial engraftment of MHC class I-deficient stem cells and reduces tumor clearance in perforin-deficient mice. J. Immunol. 167, 4230-4237.
139. Griffith, T. S., Chin, W. A., Jackson, G. C., Lynch, D. H., Kubin, M. Z. (1998) Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161, 2833-2840.
140. Mueller, C. M., Scott, D. W. (2000) Distinct molecular mechanisms of Fas resistance in murine B lymphoma cells. J. Immunol. 165, 1854-1862.
141. Tepper, C. G., Seldin, M. F. (1999) Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. Blood 94, 1727-1737.
142. Thome, M., Schneider, P., Hofmann, K., Fickenscher, H., Meinl, E., Neipel, F., Mattmann, C., Bums, K., Bodmer, J. L., Schroter, M., Scaffidi, C., Krammer, P. H., Peter, M. E., Tschopp, J. (1997) Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386, 517-521.
143. Hu, S., Vincenz, C., Ni, J., Gentz, R., Dixit, V. M. (1997) I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J. Biol. Chem. 272, 17255-17257.
144. Bertin, J., Armstrong, R. C., Ottilie, S., Martin, D. A., Wang, Y., Banks, S., Wang, G. H., Senkevich, T. G., Alnemri, E. S., Moss, B., Lenardo, M. J., Tomaselli, K. J., Cohen, J. I. (1997) Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFRI-induced apoptosis. Proc. Natl. Acad. Sci. USA 94, 1172-1176.
145. Djerbi, M., Screpanti, V., Catrina, A. I., Bogen, B., Biberfeld, P., Grandien, A. (1999) The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med. 190, 1025-1032.
146. Stamatopoulos, K., Kosmas, C., Belessi, C., Stavroyianni, N., Kyriazopoulos, P., Papadaki, T. (2000) Molecular insights into the immunopathogenesis of follicular lymphoma. Immunol. Today 21, 298-305.
147. Tsujimoto, Y., Cossman, J., Jaffe, E., Croce, C. M. (1985) Involvement of the bcl-2 gene in human follicular lymphoma. Science 228, 1440-1443.
148. McDonnell, T. J., Deane, N., Platt, F. M., Nunez, G., Jaeger, U., McKearn, J. P., Korsmeyer, S. J. (1989) bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57, 79-88.
149. Reed, J. C., Cuddy, M., Slabiak, T., Croce, C. M., Nowell, P. C. (1988) Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature 336, 259-261.
150. Strasser, A., Harris, A. W., Bath, M. L., Cory, S. (1990) Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348, 331-333.
151. Vaux, D. L., Cory, S., Adams, J. M. (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335, 440-442.
152. Fanidi, A., Harrington, E. A., Evan, G. I. (1992) Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359, 554-556.
153. Kogan, S. C., Brown, D. E., Shultz, D. B., Truong, B. T., Lallemand-Breitenbach, V., Guillemin, M. C., Lagasse, E., Weissman, I. L., Bishop, J. M. (2001) BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia. J. Exp. Med. 193, 531-543.
154. Weller, M., Malipiero, U., Aguzzi, A., Reed, J. C., Fontana, A. (1995) Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Investig. 95, 2633-2643.
155. Campos, L., Rouault, J. P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J. P., Guyotat, D. (1993) High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81, 3091-3096.
156. Hermine, O., Haioun, C., Lepage, E., d'Agay, M. F., Briere, J., Lavignac, C., Fillet, G., Salles, G., Marolleau, J. P., Diebold, J., Reyas, F., Gaulard, P. (1996) Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 87, 265-272.
157. Miyashita, T., Reed, J. C. (1992) bcl-2 Gene transfer increases relative resistance of S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 52, 5407-5411.
158. Schmitt, C. A., Rosenthal, C. T., Lowe, S. W. (2000) Genetic analysis of chemoresistance in primary murine lymphomas. Nat. Med. 6, 1029-1035.
159. Findley, H. W., Gu, L., Yeager, A. M., Zhou, M. (1997) Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 89, 2986-2993.
160. Coustan-Smith, E., Kitanaka, A., Pui, C. H., McNinch, L., Evans, W. E., Raimondi, S. C., Behm, F. G., Arico, M., Campana, D. (1996) Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 87, 1140-1146.
161. Henderson, S., Huen, D., Rowe, M., Dawson, C., Johnson, G., Rickinson, A. (1993) Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc. Natl. Acad. Sci. USA 90, 8479-8483.
162. Pearson, G. R., Luka, J., Petti, L., Sample, J., Birkenbach, M., Braun, D., Kieff, E. (1987) Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virology 160, 151-161.
163. Tarodi, B., Subramanian, T., Chinnadurai, G. (1994) Epstein-Barr virus BHRF1 protein protects against cell death induced by DNA-damaging agents and heterologous viral infection. Virology 201, 404-407.
164. Sarid, R., Sato, T., Bohenzky. R. A., Russo, J. J., Chang, Y. (1997) Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat. Med. 3, 293-298.
165. Boise, L. H., Gonzalez-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nunez, G., Thompson, C. B. (1993) bcl-x, a bcl-2-Related gene that functions as a dominant regulator of apoptotic cell death. Cell 74, 597-608.
166. Dole, M. G., Jasty, R., Cooper, M. J., Thompson, C. B., Nunez, G., Castle, V. P. (1995) Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res. 55, 2576-2582.
167. Minn, A. J., Rudin, C. M., Boise, L. H., Thompson, C. B. (1995) Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86, 1903-1910.
168. Zhou, P., Qian, L., Kozopas, K. M., Craig, R. W. (1997) Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 89, 630-643.
169. Reed, J. C. (2001) The Survivin saga goes in vivo. J. Clin. Investig. 108, 965-969.
170. Ambrosini, G., Adida, C., Altieri, D. C. (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3, 917-921.
171. Adida, C., Berrebi, D., Peuchmaur, M., Reyes-Mugica, M., Altieri, D. C. (1998) Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351, 882-883.
172. Grossman, D., Kim, P. J., Blanc-Brude, O. P., Brash, D. E., Tognin, S., Marchisio, P. C., Altieri, D. C. (2001) Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J. Clin. Investig. 108, 991-999.
173. Grossman, D., Kim, P. J., Schechner, J. S., Altieri, D. C. (2001) Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl. Acad. Sci. USA 98, 635-640.
174. Mesri, M., Wall, N. R., Li, J., Kim R. W., Altieri, D. C. (2001) Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Investig. 108, 981-990.
175. Dierlamm, J., Baens, M., Wlodarska, I., Stefanova-Ouzounova, M., Hernandez, J. M., Hossfeld, D. K., De Wolf-Peeters, C., Hagemeijer, A., Van den Berghe, H., Marynen, P. (1999) The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11; 18)(q21;q21)p6ssociated with mucosa-associated lymphoid tissue lymphomas. Blood 93, 3601-3609.
176. Bird, C. H., Sutton, V. R., Sun, J., Hirst, C. E., Novak, A., Kumar, S., Trapani, J. A., Bird, P. I. (1998) Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol. Cell. Biol. 18, 6387-6398.
177. Medema, J. P., de Jong, J., Peltenburg, L. T., Verdegaal, E. M., Gorter, A., Bres, S. A., Franken, K. L., Hahne, M., Albar, J. P., Melief, C. J., Offringa, R. (2001) Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc. Natl. Acad. Sci. USA 98, 11515-11520.
178. Bladergroen, B. A., Meijer, C. J., ten Berge, R. L., Hack, C. E., Muris, J. J., Dukers, D. F., Chott, A., Kazama, Y., Oudejans, J. J., van Berkum, O., Kummer, J. A. (2002) Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? Blood 99, 232-237.
179. Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Barr, P. J., Mountz, J. D. (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263, 1759-1762.
180. Midis, G. P., Shen, Y., Owen-Schaub, L. B. (1996) Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res. 56, 3870-3874.
181. Ugurel, S., Rappl, G., Tilgen, W., Reinhold, U. (2001) Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin. Cancer Res. 7, 1282-1286.
182. Gerharz, C. D., Ramp, U., Dejosez, M., Mahotka, C., Czarnotta, B., Bretschneider, U., Lorenz, I., Muller, M., Krammer, P. H., Gabbert, H. E. (1999) Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control. Lab. Investig. 79, 1521-1534.
183. Bai, C., Connolly, B., Metzker, M. L., Hilliard, C. A., Liu, X., Sandig, V., Soderman, A., Galloway, S. M., Liu, Q., Austin, C. P., Caskey, C. T. (2000) Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc. Natl. Acad. Sci. USA 97, 1230-1235.
184. Roth, W., Isenmann, S., Nakamura, M., Platten, M., Wick, W., Kleihues, P., Bahr, M., Ohgaki, H., Ashkenazi, A., Weller, M. (2001) Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res. 61, 2759-2765.
185. Lehmann, C., Zeis, M., Schmitz, N., Uharek, L. (2000) Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. Blood 96, 594-600.
186. Strand, S., Hofmann, W. J., Hug, H., Muller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., Galle, P. R. (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat. Med. 2, 1361-1366.
187. Higaki, K., Yano, H., Kojiro, M. (1996) Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Am. J. Pathol. 149, 429-437.
188. Moller, P., Koretz, K., Leithauser, F., Bruderlein, S., Henne, C., Quentmeier, A., Krammer, P. H. (1994) Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer 57, 371-377.
189. Leithauser, F., Dhein, J., Mechtersheimer, G., Koretz, K., Bruderlein, S., Henne, C., Schmidt, A., Debatin, K. M., Krammer, P. H., Moller, P. (1993) Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Investig. 69, 415-429.
190. Volkmaun, M., Schiff, J. H., Hajjar, Y., Otto, G., Stilgenbauer, F., Fiehn, W., Galle, P. R., Hofmann, W. J. (2001) Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma. J. Mol. Med. 79, 594-600.
191. Peli, J., Schroter, M., Rudaz, C., Hahne, M., Meyer, C., Reichmann, E., Tschopp, J. (1999) Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. EMBO J. 18, 1824-1831.
192. Maeda, T., Yamada, Y., Moriuchi, R., Sugahara, K., Tsuruda, K., Joh, T., Atogami, S., Tsukasaki, K., Tomonaga, M., Kamihira, S. (1999) Fas gene mutation in the progression of adult T cell leukemia. J. Exp. Med. 189, 1063-1071.
193. Landowski, T. H., Qu, N., Buyuksal, I., Painter, J. S., Dalton, W. S. (1997) Mutations in the Fas antigen in patients with multiple myeloma. Blood 90, 4266-4270.
194. Cascino, I., Papoff, G., De Maria, R., Testi, R., Ruberti, G. (1996) Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J. Immunol. 156, 13-17.
195. Straus, S. E., Jaffe, E. S., Puck, J. M., Dale, J. K., Elkon, K. B., Rosen-Wolff, A., Peters, A. M., Sneller, M. C., Hallahan, C. W., Wang, J., Fischer, R. E., Jackson, C. M., Lin, A. Y., Baumler, C., Siegert, E., Marx, A., Vaishnaw, A. K., Grodzicky, T., Fleisher, T. A., Lenardo, M. J. (2001) The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 98, 194-200.
196. Shin, M. S., Kim, H. S., Lee, S. H., Park, W. S., Kim, S. Y., Park, J. Y., Lee, J. H., Lee, S. K., Lee, S. N., Jung, S. S., Han, J. Y., Kim, H., Lee, J. Y., Yoo, N. J. (2001) Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res. 61, 4942-4946.
197. Fisher, M. J., Virmani, A. K., Wu, L., Aplenc, R., Harper, J. C., Powell, S. M., Rebbeck, T. R., Sidransky, D., Gazdar, A. F., El-Deiry, W. S. (2001) Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin. Cancer Res. 7, 1688-1697.
198. Pai, S. I., Wu, G. S., Ozoren, N., Wu, L., Jen, J., Sidransky, D., El-Deiry, W. S. (1998) Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 58, 3513-3518.
199. Lee, S. H., Shin, M. S., Kim, H. S., Lee, H. K., Park, W. S., Kim, S. Y., Lee, J. H., Han, S. Y., Park, J. Y., Oh, R. R., Jang, J. J., Han, J. Y., Lee, J. Y., Yoo, N. J. (1999) Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res. 59, 5683-5686.
200. Teitz, T., Wei, T., Valentine, M. B., Vanin, E. F., Grenet, J., Valentine, V. A., Behm, F. G., Look, A. T., Lahti, J. M., Kidd, V. J. (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 6, 529-535.
201. Rampino, N., Yamamoto, H., Ionov, Y., Li, Y., Sawai, H., Reed, J. C., Perucho, M. (1997) Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275, 967-969.
202. Meijerink, J. P., Mensink, E. J., Wang, K., Sedlak, T. W., Sloetjes, A. W., de Witte, T., Waksman, G., Korsmeyer, S. J. (1998) Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 91, 2991-2997.
203. Molenaar, J. J., Gerard, B., Chambon-Pautas, C., Cave, H., Dural, M., Vilmer, E., Grandchamp, B. (1998) Microsatellite instability and frameshift mutations in BAX and transforming growth factor-beta RII genes are very uncommon in acute lymphoblastic leukemia in vivo but not in cell lines. Blood 92, 230-233.
204. Krajewski, S., Blomqvist, C., Franssila, K., Krajewska, M., Wasenius, V. M., Niskanen, E., Nordling, S., Reed, J. C. (1995) Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 55, 4471-4478.
205. Yin, C., Knudson, C. M., Korsmeyer, S. J., Van Dyke, T. (1997) Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385, 637-640.
206. Bargou, R. C., Wagener, C., Bommert, K., Mapara, M. Y., Daniel, P. T., Arnold, W., Dietel, M., Guski, H., Feller, A., Royer, H. D., Dorken, B. (1996) Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J. Clin. Investig. 97, 2651-2659.
207. Ionov, Y., Yamamoto, H., Krajewski, S., Reed, J. C., Perucho, M. (2000) Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc. Natl. Acad. Sci. USA 97, 10872-10877.
208. Soengas, M. S., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, X., McCombie, R., Herman, J. G., Gerald, W. L., Lazebnik, Y. A., Cordon-Cardo, C., Lowe, S. W. (2001) Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207-211.
209. Krammer, P. H. (1997) The tumor strikes back. Cell Death Differ. 4, 362-364.
210. Igney, F. H., Behrens, C. K., Krammer, P. H. (2000) Tumor counterattack - concept and reality. Eur. J. Immunol. 30, 725-731.
211. Walker, P. R., Saas, P., Dietrich, P. Y. (1998) Tumor expression of Fas ligand (CD95L) and the consequences. Curr. Opin. Immunol, 10, 564-572.
212. French, L. E., Hahne, M., Viard, I., Radlgruber, G., Zanone, R., Becker, K., Muller, C., Tschopp, J. (1996) Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell Biol. 133, 335-343.
213. Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., Ferguson, T. A. (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189-1192.
214. Stuart, P. M., Griffith, T. S., Usui, N., Pepose, J., Yu, X., Ferguson, T. A. (1997) CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Investig. 99, 396-402.
215. Griffith, T. S., Yu, X., Herndon, J. M., Green, D. R., Ferguson, T. A. (1996) CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 5, 7-16.
216. Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., Duke, R. C. (1995) A role for CD95 ligand in preventing graft rejection. Nature 377, 630-632.
217. Allison, J., Georgiou, H. M., Strasser, A., Vaux, D. L. (1997) Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA 94, 3943-3947.
218. Saas, P., Walker, P. R., Hahne, M., Quiquerez, A. L., Schnuriger, V., Perrin, G., French, L., Van Meir, E. G., de Tribolet, N., Tschopp, J., Dietrich, P. Y. (1997) Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Investig. 99, 1173-1178.
219. Choi, C., Park, J. Y., Lee, J., Lim, J. H., Shin, E. C., Ahn, Y. S., Kim, C. H., Kim, S. J., Kim, J. D., Choi, I. S., Choi, I. H. (1999) Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-alpha, or IFN-gamma. J. Immunol. 162, 1889-1895.
220. Lau, H. T., Yu, M., Fontana, A., Stoeckert Jr., C. J. (1996) Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273, 109-112.
221. Kang, S. M., Hoffmann, A., Lc, Le, D., Springer, M. L., Stock, P. G., Blau, H. M. (1997) Immune response and myoblasts that express Fas ligand., Science 278, 1322-1324.
222. Strand, S., Galle, P. R. (1998) Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol. Med. Today 4, 63-68.
223. Bennett, M. W., O'Connell, J., O'Sullivan, G. C., Brady, C., Roche, D., Collins, J. K., Shanahan, F. (1998) The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160, 5669-5675.
224. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bomand, T., Fontana, A., Lienard, D., Cerottini, J., Tschopp, J. (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363-1366.
225. Mariani, S. M., Krammer, P. H. (1998) Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur. J. Immunol. 28, 973-982.
226. O'Connell, J., O'Sullivan, G. C., Collins, J. K., Shanahan, F. (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184, 1075-1082.
227. Villunger, A., Egle, A., Marschitz, I., Kos, M., Bock, G., Ludwig, H., Geley, S., Kofler, R., Greil, R. (1997) Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood 90, 12-20.
228. Nishimatsu, H., Takeuchi, T., Ueki, T., Kajiwara, T., Moriyama, N., Ishida, T., Li, B., Kakizoe, T., Kitamura, T. (1999) CD95 ligand expression enhances growth of murine renal cell carcinoma in vivo. Cancer Immunol. Immunother. 48, 56-61.
229. Arai, H., Chan, S. Y., Bishop, D. K., Nabel, G. J. (1997) Inhibition of the alloantibody response by CD95 ligand. Nat. Med. 3, 843-848.
230. Restifo, N. P. (2001) Countering the 'counterattack' hypothesis. Nat. Med. 7, 259.
231. Kang, S. M., Schneider, D. B., Lin, Z., Hanahan, D., Dichek, D. A., Stock, P. G., Baekkeskov, S. (1997) Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3, 738-743.
232. Allison, J., Georgiou, H. M., Strasser, A., Vaux, D. L. (1997) Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA 94, 3943-3947.
233. Judge, T. A., Desai, N. M., Yang, Z., Rostami, S., Alonso, L., Zhang, H., Chen, Y., Markman, J. F., DeMateo, R. P., Barker, C. F., Naji, A., Turka, L. A. (1998) Utility of adenoviral-mediated Fas ligand gene transfer to modulate islet allograft survival. Transplantation 66, 426-434.
234. Takeuchi, T., Ueki, T., Nishimatsu, H., Kajiwara, T., Ishida, T., Jishage, K., Ueda, O., Suzuki, H., Li, B., Moriyama, N., Kitamura, T. (1999) Accelerated rejection of Fas ligand-expressing heart grafts. J. Immunol. 162, 518-522.
235. Behrens, C. K., Igney, F. H., Arnold, B., Moller, P., Krammer, P. H. (2001) CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice. J. Immunol. 166, 3240-3247.
236. Seino, K., Kayagaki, N., Okumura, K., Yagita, H. (1997) Antitumor effect of locally produced CD95 ligand. Nat. Med. 3, 165-170.
237. Shimizu, M., Fontana, A., Takeda, Y., Yagita, H., Yoshimoto, T., Matsuzawa, A. (1999) Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells. J. Immunol. 162, 7350-7357.
238. Okamoto, S., Takamizawa, S., Bishop, W., Wen, J., Kimura, K., Sandler, A. (1999) Overexpression of Fas ligand does not confer immune privilege to a pancreatic beta tumor cell line (betaTC-3). J. Surg. Res. 84, 77-81.
239. Yagita, H., Seino, K., Kayagaki, N., Okumura, K. (1996) CD95 ligand in graft rejection. Nature 379, 682.
240. Arai, H., Gordon, D., Nabel, E. G., Nabel, G. J. (1997) Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. USA 94, 13862-13867.
241. Seino, K., Iwabuchi, K., Kayagaki, N., Miyata, R., Nagaoka, I., Matsuzawa, A., Fukao, K., Yagita, H., Okumura, K. (1998) Chemotactic activity of soluble Fas ligand against phagocytes. J. Immunol. 161, 4484-4488.
242. Ottonello, L., Tortolina, G., Amelotti, M., Dallegri, F. (1999) Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J. Immunol. 162, 3601-3606.
243. Shudo, K., Kinoshita, K., Imamura, R., Fan, H., Hasumoto, K., Tanaka, M., Nagata, S., Suda, T. (2001) The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity. Eur. J. Immunol. 31, 2504-2511.
244. Hohlbaum, A. M., Moe, S., Marshak-Rothstein, A. (2000) Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J. Exp. Med. 191, 1209-1220.
245. Kang, S. M., Braat, D., Schneider, D. B., O'Rourke, R. W., Lin, Z., Ascher, N. L., Dichek, D. A., Baekkeskov, S., Stock, P. G. (2000) A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants. Transplantation 69, 1813-1817.
246. Miwa, K., Asano, M., Horai, R., Iwakura, Y., Nagata, S., Suda, T. (1998) Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat. Med. 4, 1287-1292.
247. Hohlbaum, A. M., Gregory, M. S., Ju, S. T., Marshak-Rothstein, A. (2001) Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J. Immunol. 167, 6217-6224.
248. Rescigno, M., Piguet, V., Valzasina, B., Lens, S., Zubler, R., French, L., Kindler, V., Tschopp, J., Ricciardi-Castagnoli, P. (2000) Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses. J. Exp. Med. 192, 1661-1668.
249. Muller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., Galle, P. R. (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Investig. 99, 403-413.
250. Friesen, C., Herr, I., Krammer, P. H., Debatin, K. M. (1996) Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 2, 574-577.
251. Scaffidi, C., Kirchhoff, S., Krammer, P. H., Peter, M. E. (1999) Apoptosis signaling in lymphocytes. Curr. Opin. Immunol. 11, 277-285.
252. Klas, C., Debatin, K. M., Jonker, R. R., Krammer, P. H. (1993) Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol. 5, 625-630.
253. Ehl, S., Hoffmann-Rohrer, U., Nagata, S., Hengartner, H., Zinkernagel, R. (1996) Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo. J. Immunol. 156, 2357-2360.
254. Chen, J. J., Sun, Y., Nabel, G. J. (1998) Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282, 1714-1717.
255. Giovarelli, M., Musiani, P., Garotta, G., Ebner, R., Di Carlo, E., Kim, Y., Cappello, P., Rigamonti, L., Bernabei, P., Novelli, F., Modesti, A., Coletti, A., Ferrie, A. K., Lollini, P. L., Ruben, S., Salcedo, T., Forni, G. (1999) A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. J. Immunol. 163, 4886-4893.
256. Mellado, M., de Ana, A. M., Moreno, M. C., Martinez, C., RodriguezFrade, J. M. (2001) A potential immune escape mechanism by melanoma cells through the activation of chemokine-induced T cell death. Curr. Biol. 11, 691-696.
257. Keane, M. M., Ettenberg, S. A., Nau, M. M., Russell, E. K., Lipkowitz, S. (1999) Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 59, 734-741.
258. Chinnaiyan, A. M., Prasad, U., Shankar, S., Hamstra, D. A., Shanaiah, M., Chenevert, T. L., Ross, B. D., Rehemtulla, A. (2000) Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. USA 97, 1754-1759.
259. Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., van Elsas, A., Muller, M., Wolff, K., Eichler, H. G., Pehamberger, H. (1998) bcl-2 Antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med. 4, 232-234.
260. Zamore, P. D. (2001) RNA interference: listening to the sound of silence. Nat. Struct. Biol. 8, 746-750.